Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies

Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods: To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results: An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions: The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation.

[1]  James G. Bollinger,et al.  Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers , 2021, Brain communications.

[2]  K. Blennow,et al.  Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression , 2020, Alzheimer's research & therapy.

[3]  K. Blennow,et al.  Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment , 2020, Alzheimer's Research & Therapy.

[4]  H. Holling,et al.  Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. , 2020, Journal of Alzheimer's disease : JAD.

[5]  O. Hansson,et al.  Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease , 2020, JAMA neurology.

[6]  D. Walsh,et al.  Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease , 2020, Brain : a journal of neurology.

[7]  K. Blennow,et al.  Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2020, Translational Psychiatry.

[8]  R. Bateman,et al.  Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease , 2020, The Journal of experimental medicine.

[9]  J. Trojanowski,et al.  Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative , 2020, Molecular Psychiatry.

[10]  R. Killiany,et al.  A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease , 2020, Neurobiology of Aging.

[11]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[12]  J. Molinuevo,et al.  Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort , 2020, Journal of Alzheimer's disease : JAD.

[13]  K. Blennow,et al.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.

[14]  P. Manzine,et al.  Blood-based biomarkers of Alzheimer's disease: the long and winding road. , 2020, Current pharmaceutical design.

[15]  S. Burnham,et al.  Blood-based molecular biomarkers for Alzheimer’s disease , 2019, Molecular Brain.

[16]  D. Aarsland,et al.  Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort , 2019, Journal of Neural Transmission.

[17]  W. M. van der Flier,et al.  Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result , 2018, Front. Aging Neurosci..

[18]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[19]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[20]  R. Dobson,et al.  A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication , 2017, Journal of Alzheimer's disease : JAD.

[21]  O. Sabri,et al.  Clinical Use and Utility of Amyloid Imaging , 2017, The Journal of Nuclear Medicine.

[22]  K. Blennow.  A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood , 2017, Neurology and Therapy.

[23]  M. Laakso,et al.  The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology , 2017, Alzheimer's Research & Therapy.

[24]  Y. Bao,et al.  Low levels of ficolin-3 are associated with diabetic peripheral neuropathy , 2016, Acta Diabetologica.

[25]  S. Lovestone,et al.  Blood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology , 2015, Front. Neurol..

[26]  Lennart Thurfjell,et al.  Blood protein predictors of brain amyloid for enrichment in clinical trials? , 2015, Alzheimer's & dementia.

[27]  Magda Tsolaki,et al.  Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology , 2014, Alzheimer's & Dementia.

[28]  Magda Tsolaki,et al.  Plasma proteins predict conversion to dementia from prodromal disease , 2014, Alzheimer's & Dementia.

[29]  Simone Lista,et al.  Blood and plasma-based proteomic biomarker research in Alzheimer's disease , 2013, Progress in Neurobiology.

[30]  Magda Tsolaki,et al.  Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden , 2012, PloS one.

[31]  Y. Bao,et al.  Low serum levels of the innate immune component ficolin-3 is associated with insulin resistance and predicts the development of type 2 diabetes. , 2012, Journal of molecular cell biology.

[32]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.

[33]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[34]  J. Chalmers,et al.  Human L-Ficolin (Ficolin-2) and Its Clinical Significance , 2012, Journal of biomedicine & biotechnology.

[35]  Markus Rudin,et al.  Contrast-Enhanced Magnetic Resonance Microangiography Reveals Remodeling of the Cerebral Microvasculature in Transgenic ArcAβ Mice , 2012, The Journal of Neuroscience.

[36]  Yi Zhang,et al.  Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease , 2011, PloS one.

[37]  S. LeBlanc,et al.  Incidence of Post‐Dural Puncture Headache in Research Volunteers , 2011, Headache.

[38]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[39]  L. Ferrucci,et al.  Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. , 2011, Journal of Alzheimer's disease : JAD.

[40]  S. Strickland,et al.  Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization , 2010, Proceedings of the National Academy of Sciences.

[41]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[42]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[43]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[44]  Rong Zeng,et al.  Localized-Statistical Quantification of Human Serum Proteome Associated with Type 2 Diabetes , 2008, PloS one.

[45]  J. Ryu,et al.  A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.

[46]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[47]  T. Fujita,et al.  The lectin‐complement pathway – its role in innate immunity and evolution , 2004, Immunological reviews.

[48]  Ronald C Petersen,et al.  Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.

[49]  D. Kovacs.  α2-Macroglobulin in late-onset Alzheimer's disease , 2000, Experimental Gerontology.

[50]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[51]  C. T. Hehir,et al.  Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. , 2016, Journal of Alzheimer's disease : JAD.

[52]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.